News | December 07, 2025
Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Subscribe To Our Newsletter & Stay Updated
